Menopausal changes in the myometrium: An investigation using a GnRH agonist model

International Journal of Gynecological Pathology

Volumn 18, Issue 3, 1999, Pages 226-232

  Weeks, Andrew D ^a   Wilkinson, Nafisa ^a   Arora, Deep S ^a   Duffy, Sean R G ^a   Wells, Mike ^b   Walker, James J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Factor VIII; Gonadotrophin releasing hormone agonists; Menopause; Myometrium; Uterus; Vascularity

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MENOPAUSE; MYOMETRIUM; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERUS BLOOD FLOW; UTERUS CONTRACTILITY;

EID: 0033055327     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199907000-00007     Document Type: Article

References (26)

1. Batra S. Hormonal control of myometrial function. In: Chard T, Grudzinskas JG, eds. The uterus. Cambridge, UK: Cambridge University Press, 1994:173-92.
2. Carr BR, Marshbum PB, Weatherall PT. An evaluation of the effect of gonadotrophin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonant imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23.
3. Demopoulos RI, Jones KY, Mittal KR, Vamvakas EC. Histology of leiomyoma in patients treated with leuprolide acetate. Int J Gynecol Pathol 1997;16:131-7.
4. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotrophin-releasing hormone agonists. Hum Pathol 1993;24:1073-7.
5. Sreenan JJ, Prayson RA, Biscotti CV, Thornton MH, Easley KA, Hart WR. Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls. Am J Surg Pathol 1996;20:427-32.
6. Gutmann JN, Thornton KL, Diamond MP, Carcangiu ML. Evaluation of leuprorelide acetate treatment on histopathology of uterine myomata. Fertil Steril 1994;61:622-6.
7. Crow J, Gardner RL, McSweeney G, Shaw RW. Morphological changes in uterine leiomyomas treated by GnRH agonist Goserelin. Int J Gynecol Pathol 1995;14:235-42.
8. Malta WHM, Stabile I, Shaw RW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving gonadotrophin-releasing hormone agonist buserelin. Fertil Steril 1988;46:1083-5.
9. Weeks AD, Massmann AG, Monaghan JM, Crowther D, Duffy SRG, Walker JJ, Figueroa JP. Decrease in protein expression of uterine myometrial type 1 nitric oxide synthase in nonpregnant women as a result of decreasing estrogen. Am J Obstet Gynecol 1999, in press.
10. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effect of estrogen. FASEB J 1996;10:615-24.
11. Rutgers JL, Spong CY, Sinow R, Heiner J. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 1995;86:386-8.
12. Ruiter DJ, Schlingemann RO, Rietveld FJR, de Waal RMW. Monoclonal antibody-defined human endothelial antigens as vascular markers. J Invest Dermatol 1989;93:25S-32S.
13. Pesonen E, Martimo P, Rapola J. Histometry of the arterial wall. Lab Invest 1974;30:50-5.
14. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angio-genesis and metastatic-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
15. Weeks AD, Duffy SRG, Walker JJ. Uterine ultrasonographic changes with gonadotrophin-releasing hormone agonists. Am J Obstet Gynecol 180: 8-13, 1999
16. Ross R, Klebanoff SJ. Fine structural changes in uterine smooth muscle and fibroblasts in response to oestrogen. J Cell Biol 1967;32:155-67.
17. Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factors I and II by explant culture of fibroids and myometrium from women treated with gonadotrophin releasing hormone agonist. Obstet Gynecol 1990;76:388-94.
18. Lumsden MA, West CP, Bramley T, Rumgay L, Baird T. The binding of epidermal growth factor to human uterus and leimyomata in women rendered hypoestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol 1988;95:1299-304.
19. Huang SC, Chou CY, Lin YS, Tsai YC, Hsu KF, Liu CH, Huang KE. Enhanced DNA damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotrophin releasing hormone agonist. Am J Obstet Gynecol 1997;177:417-24.
20. Rein MS, Barbieri RL, Welch W, Gleason RE, Caulfield JP, Friedman AJ. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Obstet Gynecol 1993;82:901-5.
21. Robertson WB, Becker AE. Morphology and pathophysiology of the vascular system. In: Symmers WStC, ed. Systematic pathology, vol. 10, 3rd ed. Edinburgh: Churchill Livingstone, 1993:326.
22. Lee RMKW, Owens GK, Scott-Burden T, Head RJ, Mulvany MJ, Schiffrin EL. Pathophysiology of smooth muscle in hypertension. Can J Physiol Pharmacol 1995;73:574-84.
23. Crawford BS, Davies J, Harrigill K. Uterine artery atherosclerotic disease: histological features and clinical correlation. Obstet Gynecol 1997;90:210-5.
24. Punnonen R, Jokela H, Heinonen P, Aine R, Dastidar P. Hormone replacement therapy and atherosclerosis. J Reprod Med 1995;40:267-72.
25. McCoy MJ. Angina and myocardial infarction with use of leuprolide acetate. Am J Obstet Gynecol 1994;171:275-6.
26. Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995;91:755-63.